ClinicalTrials.gg
CompletedNCT00301262Updated Feb 1, 2021Results posted

Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied

A Phase 4 interventional study of Viagra (Sildenafil citrate) in Impotence, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 27 sites in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
17th of 50
183 · median 108
Started
2005
with 11 others
Phase 4
30 of 50
none open now
Registered
15th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 17th largest by enrollment, is one of 12 that started in 2005, is one of 30 in phase 4, and was the 15th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

Men's quality of life (QoL) is potentially affected by mild erectile dysfunction (ED) to the same extent as it is by moderate and severe ED. This study will provide controlled clinical data measuring efficacy, QoL parameters and satisfaction changes in men with mild ED treated with Viagra versus those treated with a placebo. With an open-label extension, this study will also provide all study subjects the opportunity to receive the active drug treatment for 6 weeks.

03

Conditions studied

  • Impotence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men above age of majority
  • Mild erectile dysfunction (IIEF-EF 22-25) and sexual dissatisfaction (IIEF-OS 7 or less)

Exclusion criteria

Exclusion Criteria:

  • Use of more than 4 doses of any PDE5 inhibitor in the past 12 weeks and use of any PDE5 inhibitor in the past 4 weeks
  • Subjects currently taking any other commercially available drug or non-drug treatment for ED
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
183 participants (actual)
06

What researchers measure

Primary outcomes

  1. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8)

    adjusted mean : Possible scores for the EDITS Index range from 0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction).

    Time frame: Week 8

Secondary outcomes

  1. Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index

    Possible scores for the EDITS Index range from 0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction).

    Time frame: Week 8, Week 14

  2. Change From Baseline to End of Double-Blind Phase (Week 8) in Patient Reported Erectile Function Assessment (PREFA) Total Score

    adjusted mean change; PREFA Total Score: 8 = worst; 32 = best.

    Time frame: Week 8

  3. Patient Reported Erectile Function Assessment (PREFA) Total Score

    PREFA Total Score: 8 = worst, 32 = best.

    Time frame: Week 8, Week 14

  4. Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Erectile Function

    adjusted mean change - Possible total scores for IIEF-EF range from 1 (worst) to 30 (best).

    Time frame: Week 8

  5. Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function

    adjusted mean change - Possible total scores for IIEF-OF range from 0 (worst) to 10 (best).

    Time frame: Week 8

  6. Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire

    adjusted mean change - Possible total scores for IIEF-SD range from 2 (worst) to 10 (best).

    Time frame: Week 8

  7. Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction

    adjusted mean - Possible total scores for IIEF-IS range from 0 (worst) to 15 (best).

    Time frame: Week 8

  8. Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction

    adjusted mean change - Possible total scores for IIEF-OS range from 2 (worst) to 10 (best).

    Time frame: Week 8

  9. International Index of Erectile Function (IIEF) Domain Scores- Erectile Function

    Possible total scores for IIEF-EF range from 1 (worst) to 30 (best).

    Time frame: Week 8, Week 14

  10. International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function

    Possible total scores for IIEF-OF range from 0 (worst) to 10 (best).

    Time frame: Week 8, Week 14

  11. International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire

    Possible total scores for IIEF-SD and IIEF-OS range from 2 (worst) to 10 (best).

    Time frame: Week 8, Week 14

  12. International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction

    Possible total scores for IIEF-IS range from 0 (worst) to 15 (best).

    Time frame: Week 8, Week 14

  13. International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction

    Possible total scores for IIEF-SD and IIEF-OS range from 2 (worst) to 10 (best).

    Time frame: Week 8, Week 14

  14. Change From Baseline to End of DB Phase (Week 8) in Erectile Distress Scale (EDS) Total Score

    adjusted mean change - Possible total scores for EDS range from 5 (all of the time) to 30 (none of the time). Higher scores indicate less impact of ED.

    Time frame: Week 8

  15. Erectile Distress Scale (EDS) Total Score

    Possible total scores for EDS range from 5 (all of the time) to 30 (none of the time). Higher scores indicate less impact of ED.

    Time frame: Week 8, Week 14

  16. Change From Baseline to End of DB Phase (Week 8) in Quality of Erection Questionnaire (QEQ) Total Score

    adjusted mean change - QEQ raw total score (defined as the sum of scores from QEQ Questions 1 and 3 to 7 and ranged from 6 to 30) was transformed to QEQ total score on a scale of 0 (lowest) to 100 (highest).

    Time frame: Week 8

  17. Quality of Erection Questionnaire (QEQ) Total Score

    QEQ raw total score (defined as the sum of scores from QEQ Questions 1 and 3 to 7 and ranged from 6 to 30) was transformed to QEQ total score on a scale of 0 (lowest) to 100 (highest).

    Time frame: Week 8, Week 14

  18. Global Efficacy Question 1 (GEQ1) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)

    GEQ 1: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your erections?Responder was defined as answering "Yes". % of responders/non-responders was calculated based on subjects who attempted intercourse.

    Time frame: Week 8, Week 14

  19. Global Efficacy Question 2 (GEQ2) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)

    GEQ 2: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your ability to have sexual intercourse? Responder was defined as answering "Yes". % of responders/non-responders was calculated based on subjects who attempted intercourse.

    Time frame: Week 8, Week 14

  20. Global Efficacy Question 3 (GEQ3) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)

    GEQ 3: When you took a dose of study drug and had sexual stimulation, how often did you get an erection that allowed you to engage in satisfactory sexual intercourse? Resp. was defined as answering almost always or always, most times, or sometimes, and non-resp was defined as answering a few times or almost never or never.

    Time frame: Week 8, Week 14

  21. Percentage of Occasions of Successful Intercourse (Event Log)

    Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to Week 8

  22. Percentage of Occasions of Ejaculation and/or Orgasm (Event Log)

    Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to Week 8

  23. Percentage of Occasions of Successful Intercourse (Event Log)

    Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Week 8 to Week 14

  24. Percentage of Occasions of Ejaculation and/or Orgasm Event Log

    Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Week 8 to Week 14

  25. Change From Baseline to Week 8 in Analog Scales- Firmness

    mean change - scale of 0 (worst) to 10 (best).

    Time frame: baseline to Week 8

  26. Change From Baseline to Week 8 in Analog Scales- Maintenance

    mean change - scale of 0 (worst) to 10 (best).

    Time frame: baseline to Week 8

  27. Change From Baseline to Week 8 in Analog Scales- Reliability

    mean change - scale of 0 (worst) to 10 (best).

    Time frame: baseline to Week 8

  28. Change From Baseline to Week 8 in Analog Scales- General Sexual Performance

    mean change - scale of 0 (worst) to 10 (best)

    Time frame: baseline to week 8

  29. Analog Scales- Firmness

    mean - scale of 0 (worst) to 10 (best)

    Time frame: Week 8, Week 14

  30. Analog Scales- Maintenance

    mean - scale of 0 (worst) to 10 (best)

    Time frame: Week 8, Week 14

  31. Analog Scales- Reliability

    mean - scale of 0 (worst) to 10 (best)

    Time frame: Week 8, Week 14

  32. Analog Scales- General Sexual Performance

    mean - scale of 0 (worst) to 10 (best)

    Time frame: Week 8, Week 14

  33. Shift in Responder Rate From Week 8 to Week 14 for Global Efficacy Question (GEQ) 1

    GEQ 1: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your erections? Responder was defined as answering Yes to GEQ 1.

    Time frame: Week 8 to Week 14

  34. Shift in Responder Rate From Week 8 to Week 14 for GEQ2

    GEQ 2: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your ability to have sexual intercourse? Responder was defined as answering Yes to GEQ 2.

    Time frame: Week 8 to Week 14

  35. Shift in Responder Rate From Week 8 to Week 14 for GEQ3

    GEQ3: When you took a dose of study drug and had sexual stimulation, how often did you get an erection that allowed you to engage in satisfactory sexual intercourse? Responder = almost always or always, most times, or sometimes. Non-responder = a few times (much less than half the time) or almost never or never.

    Time frame: Week 8 to Week 14

  36. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 0

    Per-patient percentage of hardness of erections:Grade 0 = no erection at all. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  37. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 1

    Per-patient percentage of hardness of erections: Grade 1 = increase in size but not hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <= Week 14

  38. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 2

    Per-patient percentage of hardness of erections: Grade 2 = hard but not hard enough for penetration. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  39. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3

    Per-patient percentage of hardness of erections: Grade 3 = hard enough for penetration but not completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  40. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 4

    Per-patient percentage of hardness of erections: Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  41. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3 or 4

    Per-patient percentage of hardness of erections: Grade 3 = hard enough for penetration but not completely hard, Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  42. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 0

    Per-patient percentage of hardness of second erections: Grade 0 = no erection at all. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  43. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 1

    Per-patient percentage of hardness of second erections: Grade 1 = increase in size but not hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  44. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 2

    Per-patient percentage of hardness of second erections:Grade 2 = hard but not hard enough for penetration. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  45. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3

    Per-patient percentage of hardness of second erections:Grade 3 = hard enough for penetration but not completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  46. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 4

    Per-patient percentage of hardness of second erections:Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  47. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3 or 4

    Per-patient percentage of hardness of second erections: Grade 3 = hard enough for penetration but not completely hard, Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

  48. Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Frequency of Second Erections

    Percentage of occasions at which second erection was achieved. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

    Time frame: Baseline to <Week 8 and Week 8 to <=Week 14

07

Results

Posted Dec 9, 2008

Participant flow

31 centers in Canada

Double Blind Phase (DB)
Participant flow — Double Blind Phase (DB)
MilestoneDB Viagra / OL ViagraDB Placebo/OL Viagra
Started9482
Completed8469
Not completed1013
Withdrew: Adverse event10
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up33
Withdrew: Withdrawal by subject55
Withdrew: Other14
Open Label Phase (OL)
Participant flow — Open Label Phase (OL)
MilestoneDB Viagra / OL ViagraDB Placebo/OL Viagra
Started8369
Completed7967
Not completed42
Withdrew: Adverse event10
Withdrew: Lost to follow-up12
Withdrew: Other20

Outcome measures

PrimaryErectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8)

adjusted mean : Possible scores for the EDITS Index range from 0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8)
scores on a scaleDB ViagraDB Placebo
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index at the End of the DB Treatment (Week 8)80.27 ± 2.32962.15 ± 2.524
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = <0.0001 (Since there was only one primary endpoint no multiple comparison adjustments were made for primary analysis. Final stat. model included centre, treatment, smoking status and history of ED as factors, and age, duration of ED (baseline) as covariates.) · Mean difference (final values): 18.13 · 95% CI 11.40 to 24.86Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryErectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index

Possible scores for the EDITS Index range from 0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index79.21 ± 19.64684.12 ± 17.22061.64 ± 22.75287.42 ± 15.124
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0028 · Mean difference (net): 5.09 · 95% CI 1.800 to 8.370A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 26.02 · 95% CI 20.580 to 31.455A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryChange From Baseline to End of Double-Blind Phase (Week 8) in Patient Reported Erectile Function Assessment (PREFA) Total Score

adjusted mean change; PREFA Total Score: 8 = worst; 32 = best.

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of Double-Blind Phase (Week 8) in Patient Reported Erectile Function Assessment (PREFA) Total Score
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of Double-Blind Phase (Week 8) in Patient Reported Erectile Function Assessment (PREFA) Total Score3.97 ± 0.4982.21 ± 0.536
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0080 · Mean difference (final values): 1.76 · 95% CI 0.47 to 3.06Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryPatient Reported Erectile Function Assessment (PREFA) Total Score

PREFA Total Score: 8 = worst, 32 = best.

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
Patient Reported Erectile Function Assessment (PREFA) Total Score
scores on a scaleDB Viagra Week 8DB Viagra /OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Patient Reported Erectile Function Assessment (PREFA) Total Score28.54 ± 3.46829.58 ± 2.98826.79 ± 3.75329.73 ± 2.895
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra /OL Viagra Week 14 · paired t-test · p = 0.0051 · Mean difference (net): 0.94 · 95% CI 0.290 to 1.585A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 2.79 · 95% CI 1.812 to 3.770A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryChange From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Erectile Function

adjusted mean change - Possible total scores for IIEF-EF range from 1 (worst) to 30 (best).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Erectile Function
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Erectile Function2.08 ± 0.642-0.53 ± 0.698
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0054 · Mean difference (final values): 2.61 · 95% CI 0.78 to 4.43Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryChange From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function

adjusted mean change - Possible total scores for IIEF-OF range from 0 (worst) to 10 (best).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function0.59 ± 0.2480.30 ± 0.271
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.4232 · Mean difference (final values): 0.30 · 95% CI -0.43 to 1.02Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryChange From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire

adjusted mean change - Possible total scores for IIEF-SD range from 2 (worst) to 10 (best).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire0.60 ± 0.207-0.08 ± 0.223
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0156 · Mean difference (final values): 0.68 · 95% CI 0.13 to 1.22Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryChange From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction

adjusted mean - Possible total scores for IIEF-IS range from 0 (worst) to 15 (best).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction2.20 ± 0.3651.00 ± 0.390
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0096 · Mean difference (final values): 1.20 · 95% CI 0.30 to 2.11Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryChange From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction

adjusted mean change - Possible total scores for IIEF-OS range from 2 (worst) to 10 (best).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction2.35 ± 0.2541.46 ± 0.275
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0135 · Mean difference (final values): 0.90 · 95% CI 0.19 to 1.61Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryInternational Index of Erectile Function (IIEF) Domain Scores- Erectile Function

Possible total scores for IIEF-EF range from 1 (worst) to 30 (best).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
International Index of Erectile Function (IIEF) Domain Scores- Erectile Function
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
International Index of Erectile Function (IIEF) Domain Scores- Erectile Function24.92 ± 5.37526.43 ± 5.02322.40 ± 6.40327.67 ± 3.573
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0033 · Mean difference (net): 1.49 · 95% CI 0.0510 to 2.465A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 5.22 · 95% CI 3.676 to 6.772A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryInternational Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function

Possible total scores for IIEF-OF range from 0 (worst) to 10 (best).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
International Index of Erectile Function (IIEF) Domain Scores- Orgasmic Function8.62 ± 1.8128.95 ± 1.5987.81 ± 2.5649.21 ± 1.213
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.2581 · Mean difference (net): 0.20 · 95% CI -0.149 to 0.549A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 1.39 · 95% CI 0.758 to 2.018A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryInternational Index of Erectile Function (IIEF) Domain Scores- Sexual Desire

Possible total scores for IIEF-SD and IIEF-OS range from 2 (worst) to 10 (best).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
International Index of Erectile Function (IIEF) Domain Scores- Sexual Desire7.90 ± 1.6658.10 ± 1.5397.37 ± 1.7128.18 ± 1.230
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.2857 · Mean difference (net): 0.18 · 95% CI -0.149 to 0.499A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = 0.0005 · Mean difference (net): 0.76 · 95% CI 0.345 to 1.177A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryInternational Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction

Possible total scores for IIEF-IS range from 0 (worst) to 15 (best).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
International Index of Erectile Function (IIEF) Domain Scores- Intercourse Satisfaction11.82 ± 2.80612.64 ± 2.36710.84 ± 2.63513.12 ± 1.943
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0102 · Mean difference (net): 0.75 · 95% CI 0.183 to 1.317A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 2.28 · 95% CI 1.557 to 3.010A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryInternational Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction

Possible total scores for IIEF-SD and IIEF-OS range from 2 (worst) to 10 (best).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
International Index of Erectile Function (IIEF) Domain Scores- Overall Satisfaction8.19 ± 1.8278.94 ± 1.6567.25 ± 2.1789.12 ± 1.332
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0016 · Mean difference (net): 0.68 · 95% CI 0.264 to 1.086A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 1.90 · 95% CI 1.335 to 2.456A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryChange From Baseline to End of DB Phase (Week 8) in Erectile Distress Scale (EDS) Total Score

adjusted mean change - Possible total scores for EDS range from 5 (all of the time) to 30 (none of the time). Higher scores indicate less impact of ED.

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in Erectile Distress Scale (EDS) Total Score
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in Erectile Distress Scale (EDS) Total Score5.14 ± 0.8702.36 ± 0.926
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0083 · Mean difference (final values): 2.78 · 95% CI 0.73 to 4.83Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryErectile Distress Scale (EDS) Total Score

Possible total scores for EDS range from 5 (all of the time) to 30 (none of the time). Higher scores indicate less impact of ED.

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
Erectile Distress Scale (EDS) Total Score
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Erectile Distress Scale (EDS) Total Score24.58 ± 6.03924.55 ± 6.55221.23 ± 6.24626.58 ± 4.717
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.9146 · Mean difference (net): -0.06 · 95% CI -1.218 to 1.093A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 5.54 · 95% CI 3.961 to 7.114A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryChange From Baseline to End of DB Phase (Week 8) in Quality of Erection Questionnaire (QEQ) Total Score

adjusted mean change - QEQ raw total score (defined as the sum of scores from QEQ Questions 1 and 3 to 7 and ranged from 6 to 30) was transformed to QEQ total score on a scale of 0 (lowest) to 100 (highest).

Time frame:
Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline to End of DB Phase (Week 8) in Quality of Erection Questionnaire (QEQ) Total Score
scores on a scaleDB ViagraDB Placebo
Change From Baseline to End of DB Phase (Week 8) in Quality of Erection Questionnaire (QEQ) Total Score24.04 ± 3.2605.62 ± 3.558
Statistical analysis
  • DB Viagra vs DB Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): 18.42 · 95% CI 8.88 to 27.96Mean difference between the sidenafil group compared to the placebo group was calculated along with 95% confidence intervals for these differences.
SecondaryQuality of Erection Questionnaire (QEQ) Total Score

QEQ raw total score (defined as the sum of scores from QEQ Questions 1 and 3 to 7 and ranged from 6 to 30) was transformed to QEQ total score on a scale of 0 (lowest) to 100 (highest).

Time frame:
Week 8, Week 14
Reported as:
Mean · scores on a scale
Quality of Erection Questionnaire (QEQ) Total Score
scores on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Quality of Erection Questionnaire (QEQ) Total Score80.20 ± 23.95486.46 ± 20.91863.64 ± 28.55989.74 ± 17.473
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0064 · Mean difference (net): 6.41 · 95% CI 1.857 to 10.956A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 26.80 · 95% CI 19.636 to 33.971A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryGlobal Efficacy Question 1 (GEQ1) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)

GEQ 1: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your erections?Responder was defined as answering "Yes". % of responders/non-responders was calculated based on subjects who attempted intercourse.

Time frame:
Week 8, Week 14
Reported as:
Number · percentage of subjects
Global Efficacy Question 1 (GEQ1) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)
percentage of subjectsWeek 8 DB ViagraWeek 8 DB PlaceboWeek 14 DB Viagra/OL ViagraWeek 14 DB Placebo/OL Viagra
GEQ1 Responder81.843.890.094.0
GEQ1 Non-Responder18.256.210.06.0
Statistical analysis
  • Week 8 DB Viagra vs Week 8 DB Placebo · Regression, Logistic · p = 0.0001 · Odds ratio (or): 6.491 · 95% CI 3.042 to 13.851
SecondaryGlobal Efficacy Question 2 (GEQ2) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)

GEQ 2: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your ability to have sexual intercourse? Responder was defined as answering "Yes". % of responders/non-responders was calculated based on subjects who attempted intercourse.

Time frame:
Week 8, Week 14
Reported as:
Number · percentage of subjects
Global Efficacy Question 2 (GEQ2) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)
percentage of subjectsWeek 8 DB ViagraWeek 8 DB PlaceboWeek 14 DB Viagra/OL ViagraWeek 14 DB Placebo/OL Viagra
GEQ2 Responder79.345.286.392.5
GEQ2 Non-Responder20.754.813.87.5
Statistical analysis
  • Week 8 DB Viagra vs Week 8 DB Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.915 · 95% CI 2.396 to 10.080
SecondaryGlobal Efficacy Question 3 (GEQ3) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)

GEQ 3: When you took a dose of study drug and had sexual stimulation, how often did you get an erection that allowed you to engage in satisfactory sexual intercourse? Resp. was defined as answering almost always or always, most times, or sometimes, and non-resp was defined as answering a few times or almost never or never.

Time frame:
Week 8, Week 14
Reported as:
Number · percentage of subjects
Global Efficacy Question 3 (GEQ3) Response at End of the Double-Blind Phase (Week 8) and at End of the Open-Label Phase (Week 14)
percentage of subjectsWeek 8 DB ViagraWeek 8 DB PlaceboWeek 14 DB Viagra/OL ViagraWeek 14 DB Placebo/OL Viagra
GEQ3 Responders94.381.795.098.5
GEQ3 Non-Responders5.718.35.01.5
Statistical analysis
  • Week 8 DB Viagra vs Week 8 DB Placebo · Regression, Logistic · p = 0.0187 · Odds ratio (or): 3.676 · 95% CI 1.242 to 10.875
SecondaryPercentage of Occasions of Successful Intercourse (Event Log)

Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to Week 8
Reported as:
Mean · percentage of occasions
Percentage of Occasions of Successful Intercourse (Event Log)
percentage of occasionsDB ViagraDB Placebo
Percentage of Occasions of Successful Intercourse (Event Log)73.64 ± 26.68959.73 ± 33.332
Statistical analysis
  • DB Viagra vs DB Placebo · independent-samples t-test · p = 0.0037 · Mean difference (net): 13.90 · 95% CI 4.59 to 23.22Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryPercentage of Occasions of Ejaculation and/or Orgasm (Event Log)

Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to Week 8
Reported as:
Mean · Percentage of occasions
Percentage of Occasions of Ejaculation and/or Orgasm (Event Log)
Percentage of occasionsDB ViagraDB Placebo
Percentage of Occasions of Ejaculation and/or Orgasm (Event Log)74.31 ± 25.30064.60 ± 31.903
Statistical analysis
  • DB Viagra vs DB Placebo · independent-samples t-test · p = 0.0321 · Mean difference (net): 9.72 · 95% CI 0.84 to 18.60Mean Difference = Week 8 - Baseline
SecondaryPercentage of Occasions of Successful Intercourse (Event Log)

Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Week 8 to Week 14
Reported as:
Mean · percentage of occasions
Percentage of Occasions of Successful Intercourse (Event Log)
percentage of occasionsDB Viagra / OL ViagraDB Placebo/OL Viagra
Percentage of Occasions of Successful Intercourse (Event Log)79.65 ± 25.30987.63 ± 21.936
Statistical analysis
  • DB Viagra / OL Viagra vs DB Placebo/OL Viagra · independent-samples t-test · p = 0.0427 · Mean difference (net): -7.97 · 95% CI -15.68 to -0.27Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryPercentage of Occasions of Ejaculation and/or Orgasm Event Log

Percentage of occasions at which subjects answered yes to the question, did your erection last long enough to have successful intercourse. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Week 8 to Week 14
Reported as:
Mean · percentage of occasions
Percentage of Occasions of Ejaculation and/or Orgasm Event Log
percentage of occasionsDB Viagra / OL ViagraDB Placebo/OL Viagra
Percentage of Occasions of Ejaculation and/or Orgasm Event Log77.69 ± 25.09985.29 ± 22.257
Statistical analysis
  • DB Viagra / OL Viagra vs DB Placebo/OL Viagra · independent-samples t-test · p = 0.0533 · Mean difference (net): -7.60 · 95% CI -15.32 to 0.11Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryChange From Baseline to Week 8 in Analog Scales- Firmness

mean change - scale of 0 (worst) to 10 (best).

Time frame:
baseline to Week 8
Reported as:
Mean · units on a scale
Change From Baseline to Week 8 in Analog Scales- Firmness
units on a scaleDB ViagraDB Placebo
Change From Baseline to Week 8 in Analog Scales- Firmness1.55 ± 2.0230.38 ± 1.800
Statistical analysis
  • DB Viagra vs DB Placebo · 2-sample independent t-test · p = 0.0002 · Mean difference (net): 1.1670 · 95% CI 0.566 to 1.768A 2-sample independent t-test was used to test the difference between treatment for the change between baseline and Week 8 (change = Week 8 - baseline).
SecondaryChange From Baseline to Week 8 in Analog Scales- Maintenance

mean change - scale of 0 (worst) to 10 (best).

Time frame:
baseline to Week 8
Reported as:
Mean · units on a scale
Change From Baseline to Week 8 in Analog Scales- Maintenance
units on a scaleDB ViagraDB Placebo
Change From Baseline to Week 8 in Analog Scales- Maintenance1.84 ± 2.4210.40 ± 2.152
Statistical analysis
  • DB Viagra vs DB Placebo · 2-sample independent t-test · p = 0.0001 · Mean difference (net): 1.4454 · 95% CI 0.727 to 2.164A 2-sample independent t-test was used to test the difference between treatment for the change between baseline and Week 8 (change = Week 8 - baseline).
SecondaryChange From Baseline to Week 8 in Analog Scales- Reliability

mean change - scale of 0 (worst) to 10 (best).

Time frame:
baseline to Week 8
Reported as:
Mean · units on a scale
Change From Baseline to Week 8 in Analog Scales- Reliability
units on a scaleDB ViagraDB Placebo
Change From Baseline to Week 8 in Analog Scales- Reliability1.61 ± 2.7950.42 ± 2.081
Statistical analysis
  • DB Viagra vs DB Placebo · 2-sample independent t-test · p = 0.0032 · Mean difference (net): 1.1821 · 95% CI 0.403 to 1.961A 2-sample independent t-test was used to test the difference between treatment for the change between baseline and Week 8 (change = Week 8 - baseline).
SecondaryChange From Baseline to Week 8 in Analog Scales- General Sexual Performance

mean change - scale of 0 (worst) to 10 (best)

Time frame:
baseline to week 8
Reported as:
Mean · units on a scale
Change From Baseline to Week 8 in Analog Scales- General Sexual Performance
units on a scaleDB ViagraDB Placebo
Change From Baseline to Week 8 in Analog Scales- General Sexual Performance1.72 ± 2.3550.51 ± 2.109
Statistical analysis
  • DB Viagra vs DB Placebo · 2-sample independent t-test · p = 0.0008 · Mean difference (net): 1.2123 · 95% CI 0.511 to 1.913A 2-sample independent t-test was used to test the difference between treatment for the change between baseline and Week 8 (change = Week 8 - baseline).
SecondaryAnalog Scales- Firmness

mean - scale of 0 (worst) to 10 (best)

Time frame:
Week 8, Week 14
Reported as:
Mean · units on a scale
Analog Scales- Firmness
units on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Analog Scales- Firmness7.87 ± 1.8728.25 ± 1.9326.60 ± 2.1718.64 ± 1.264
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0195 · Mean difference (net): 0.39 · 95% CI 0.064 to 0.711A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 2.09 · 95% CI 1.551 to 2.628A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryAnalog Scales- Maintenance

mean - scale of 0 (worst) to 10 (best)

Time frame:
Week 8, Week 14
Reported as:
Mean · units on a scale
Analog Scales- Maintenance
units on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Analog Scales- Maintenance7.65 ± 2.1388.01 ± 2.1555.99 ± 2.5198.55 ± 1.617
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0186 · Mean difference (net): 0.40 · 95% CI 0.069 to 0.731A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 2.67 · 95% CI 2.044 to 3.299A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryAnalog Scales- Reliability

mean - scale of 0 (worst) to 10 (best)

Time frame:
Week 8, Week 14
Reported as:
Mean · units on a scale
Analog Scales- Reliability
units on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Analog Scales- Reliability7.35 ± 2.3607.96 ± 2.2926.04 ± 2.3068.55 ± 1.550
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0033 · Mean difference (net): 0.65 · 95% CI 0.223 to 1.077A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 2.61 · 95% CI 2.042 to 3.182A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryAnalog Scales- General Sexual Performance

mean - scale of 0 (worst) to 10 (best)

Time frame:
Week 8, Week 14
Reported as:
Mean · units on a scale
Analog Scales- General Sexual Performance
units on a scaleDB Viagra Week 8DB Viagra/OL Viagra Week 14DB Placebo Week 8DB Placebo/OL Viagra Week 14
Analog Scales- General Sexual Performance7.58 ± 2.0778.01 ± 1.9786.53 ± 2.1288.49 ± 1.319
Statistical analysis
  • DB Viagra Week 8 vs DB Viagra/OL Viagra Week 14 · paired t-test · p = 0.0143 · Mean difference (net): 0.45 · 95% CI 0.093 to 0.807A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
  • DB Placebo Week 8 vs DB Placebo/OL Viagra Week 14 · paired t-test · p = <0.0001 · Mean difference (net): 1.99 · 95% CI 1.454 to 2.516A paired t-test was used to examine the within treatment difference between week 8 and week 14 (open label phase).
SecondaryShift in Responder Rate From Week 8 to Week 14 for Global Efficacy Question (GEQ) 1

GEQ 1: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your erections? Responder was defined as answering Yes to GEQ 1.

Time frame:
Week 8 to Week 14
Reported as:
Number · subjects
Shift in Responder Rate From Week 8 to Week 14 for Global Efficacy Question (GEQ) 1
subjectsDB Viagra / OL ViagraDB Placebo/ OL Viagra
Responder at Week 8 / Responder at Week 146127
Responder at Week 8 / Non-Responder at Week 1430
Non-Responder at Week 8 / Responder at Week 141136
Non-Responder at Week 8 / Non-Responder at Week 1454
Statistical analysis
  • DB Viagra / OL Viagra · McNemar · p = 0.0325
  • DB Placebo/ OL Viagra · McNemar · p = <0.0001
SecondaryShift in Responder Rate From Week 8 to Week 14 for GEQ2

GEQ 2: Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your ability to have sexual intercourse? Responder was defined as answering Yes to GEQ 2.

Time frame:
Week 8 to Week 14
Reported as:
Number · subjects
Shift in Responder Rate From Week 8 to Week 14 for GEQ2
subjectsDB Viagra / OL ViagraDB Placebo / OL Viagra
Responder at Week 8 / Responder at Week 146029
Responder at Week 8 / Non-Responder at Week 1410
Non-Responder at Week 8 / Responder at Week 14833
Non-Responder at Week 8 / Non-Responder at Week 14105
Statistical analysis
  • DB Viagra / OL Viagra · McNemar · p = 0.0196
  • DB Placebo / OL Viagra · McNemar · p = <0.0001
SecondaryShift in Responder Rate From Week 8 to Week 14 for GEQ3

GEQ3: When you took a dose of study drug and had sexual stimulation, how often did you get an erection that allowed you to engage in satisfactory sexual intercourse? Responder = almost always or always, most times, or sometimes. Non-responder = a few times (much less than half the time) or almost never or never.

Time frame:
Week 8 to Week 14
Reported as:
Number · subjects
Shift in Responder Rate From Week 8 to Week 14 for GEQ3
subjectsDB Viagra / OL ViagraDB Placebo / OL Viagra
Responder at Week 8 / Responder at Week 147454
Responder at Week 8 / Non-Responder at Week 1400
Non-Responder at Week 8 / Responder at Week 14110
Non-Responder at Week 8 / Non-Responder at Week 1441
Statistical analysis
  • DB Viagra / OL Viagra · McNemar · p = 0.3173
  • DB Placebo / OL Viagra · McNemar · p = 0.0016
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 0

Per-patient percentage of hardness of erections:Grade 0 = no erection at all. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 0
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline to < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 07.09 ± 13.04112.64 ± 23.8344.50 ± 12.2173.12 ± 9.855
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline to < Week 8 · Independent-samples t-test · p = 0.0624 · Mean difference (net): -5.55 · 95% CI -11.39 to 0.29Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.4523 · Mean difference (net): 1.38 · 95% CI -2.24 to 5.01Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 1

Per-patient percentage of hardness of erections: Grade 1 = increase in size but not hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <= Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 1
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 13.83 ± 9.6006.31 ± 15.1443.48 ± 14.3001.88 ± 8.269
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.2081 · Mean difference (net): -2.48 · 95% CI -6.35 to 1.40Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.4131 · Mean difference (net): 1.61 · 95% CI -2.26 to 5.48Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 2

Per-patient percentage of hardness of erections: Grade 2 = hard but not hard enough for penetration. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 2
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 26.96 ± 11.8588.72 ± 15.1904.62 ± 10.0382.26 ± 7.813
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.4069 · Mean difference (net): -1.77 · 95% CI -5.97 to 2.43Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.1137 · Mean difference (net): 2.37 · 95% CI -0.57 to 5.31Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3

Per-patient percentage of hardness of erections: Grade 3 = hard enough for penetration but not completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 334.94 ± 29.25347.17 ± 32.16729.50 ± 28.51530.12 ± 31.412
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.0123 · Mean difference (net): -12.23 · 95% CI -21.77 to -2.70Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.8993 · Mean difference (net): -0.62 · 95% CI -10.27 to 9.03Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 4

Per-patient percentage of hardness of erections: Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 4
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 447.19 ± 35.29325.16 ± 33.76457.89 ± 35.93462.63 ± 35.112
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = <0.0001 · Mean difference (net): 22.03 · 95% CI 11.25 to 32.81Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.4165 · Mean difference (net): -4.74 · 95% CI -16.24 to 6.76Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3 or 4

Per-patient percentage of hardness of erections: Grade 3 = hard enough for penetration but not completely hard, Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3 or 4
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of First Erections Grade 3 or 482.13 ± 23.47672.33 ± 31.79887.39 ± 22.49692.75 ± 15.386
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.0257 · Mean difference (net): 9.80 · 95% CI 1.21 to 18.39Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.0971 · Mean difference (net): -5.36 · 95% CI -11.70 to 0.98Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 0

Per-patient percentage of hardness of second erections: Grade 0 = no erection at all. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 0
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 00.00 ± 0.0003.18 ± 15.0520.13 ± 0.9852.17 ± 14.014
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.0726 · Mean difference (net): -3.18 · 95% CI -6.66 to 0.30Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.2581 · Mean difference (net): -2.04 · 95% CI -5.61 to 1.52Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 1

Per-patient percentage of hardness of second erections: Grade 1 = increase in size but not hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 1
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 16.43 ± 22.2117.47 ± 22.3171.70 ± 9.1432.03 ± 8.638
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.8158 · Mean difference (net): -1.04 · 95% CI -9.86 to 7.78Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.8464 · Mean difference (net): -0.33 · 95% CI -3.68 to 3.02Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 2

Per-patient percentage of hardness of second erections:Grade 2 = hard but not hard enough for penetration. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 2
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 214.93 ± 28.14515.27 ± 30.43111.96 ± 24.55512.66 ± 28.294
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.9529 · Mean difference (net): -0.34 · 95% CI -11.82 to 11.13Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.8899 · Mean difference (net): -0.69 · 95% CI -10.59 to 9.20Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3

Per-patient percentage of hardness of second erections:Grade 3 = hard enough for penetration but not completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 337.41 ± 38.65847.59 ± 41.02542.97 ± 38.32233.29 ± 31.633
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.2001 · Mean difference (net): -10.18 · 95% CI -25.83 to 5.47Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.1527 · Mean difference (net): 9.68 · 95% CI -3.64 to 23.01Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 4

Per-patient percentage of hardness of second erections:Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 4
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 441.23 ± 41.01326.49 ± 34.30043.24 ± 39.89149.86 ± 36.921
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.0606 · Mean difference (net): 14.74 · 95% CI -0.67 to 30.15Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.3678 · Mean difference (net): -6.62 · 95% CI -21.12 to 7.88Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3 or 4

Per-patient percentage of hardness of second erections: Grade 3 = hard enough for penetration but not completely hard, Grade 4 = completely hard. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3 or 4
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Hardness of Second Erections Grade 3 or 478.64 ± 35.39574.08 ± 40.92286.21 ± 27.64783.14 ± 31.561
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.5429 · Mean difference (net): 4.56 · 95% CI -10.25 to 19.37Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.5849 · Mean difference (net): 3.07 · 95% CI -8.02 to 14.15Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
SecondaryBaseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Frequency of Second Erections

Percentage of occasions at which second erection was achieved. Calculation for each subject for each event log endpoint: percentage = (number of occasions with an answer of 'Yes' within visit interval) / (number of occasions within visit interval) x 100.

Time frame:
Baseline to <Week 8 and Week 8 to <=Week 14
Reported as:
Mean · percentage of occasions
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Frequency of Second Erections
percentage of occasionsDB Viagra Baseline < Week 8DB Placebo Baseline < Week 8DB Viagra/OL Viagra Week 8 to <=Week 14DB Placebo/OL Viagra Week 8 to <=Week 14
Baseline to <Week 8 and Week 8 to <=Week 14 in Event Log: Frequency of Second Erections38.06 ± 33.28719.20 ± 28.97744.07 ± 38.63239.15 ± 37.159
Statistical analysis
  • DB Viagra Baseline < Week 8 vs DB Placebo Baseline < Week 8 · Independent-samples t-test · p = 0.0002 · Mean difference (net): 18.86 · 95% CI 9.08 to 28.64Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.
  • DB Viagra/OL Viagra Week 8 to <=Week 14 vs DB Placebo/OL Viagra Week 8 to <=Week 14 · Independent-samples t-test · p = 0.4290 · Mean difference (net): 4.93 · 95% CI -7.35 to 17.20Independent-samples t-test was used to test mean difference of zero between treatment groups (Viagra - Placebo) at each visit interval.

Baseline characteristics

Age, Continuous
Age, Continuous(years)Start : DB ViagraStart : DB PlaceboTotal
Mean51.6 ± 12.548.0 ± 11.949.9 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Start : DB ViagraStart : DB PlaceboTotal
Female000
Male9482176
08

Study locations

27 sites
  • Pfizer Investigational Site
    Calgary, Alberta T2L 1K8, Canada
  • Pfizer Investigational Site
    Calgary, Alberta T2V 4R6, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T5H 4B9, Canada
  • Pfizer Investigational Site
    Langley, British Columbia V3A 4H9, Canada
  • Pfizer Investigational Site
    Surrey, British Columbia V3V 1N1, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V5Z 1K3, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8T 5G1, Canada
  • Pfizer Investigational Site
    Bay Roberts, Newfoundland and Labrador A0A 1G0, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Pfizer Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • Pfizer Investigational Site
    Corunna, Ontario N0N 1G0, Canada
  • Pfizer Investigational Site
    Kingston, Ontario K7L 3J7, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 4V2, Canada
  • Pfizer Investigational Site
    Oakville, Ontario L6H 3P1, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5T 2S8, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M6A 3B5, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec G7H 4A3, Canada
  • Pfizer Investigational Site
    L'Ancienne-Lorette, Quebec G2E 2X1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2X 1N8, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3S 1Z1, Canada
  • Pfizer Investigational Site
    Montréal, Quebec H2X 1N8, Canada
  • Pfizer Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Pfizer Investigational Site
    St. Leonard, Quebec H1S 3A9, Canada
09

References and documents

Publications

  • Kaminetsky JC, Stecher V, Tseng LJ. Quality of erections by age group in men with erectile dysfunction. Int J Clin Pract. 2017 Oct;71(10). doi: 10.1111/ijcp.12976. Epub 2017 Sep 11. PubMed 28892218 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2008, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2006
First posted
Mar 10, 2006
Start
Nov 2005
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Results first posted
Dec 9, 2008
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00301262
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 10, 2006
Start date
Nov 2005
Primary completion
Sep 2007
Completion
Sep 2007
Results posted
Dec 9, 2008
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion